Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Byetta does not raise pancreatitis risk, according to claims data

Executive Summary

Analysis of a UnitedHealth Group transaction database found the risk of acute pancreatitis among incretin-based diabetes therapies - Amylin/Lilly's Byetta (exenatide) and Merck's Januvia (sitagliptin) - to be similar to that associated with metformin and glyburide, both agents with established safety profiles. The study, which was sponsored by Amylin and published in Current Medical Research and Opinion March 12, concluded that more comprehensive pharmaco-epidemiology studies are needed to more fully assess the risk. A safety alert from FDA in August 2008 regarding two fatal cases of pancreatitis in Byetta patients sparked a decline in sales, although analysts suggested that nausea associated with initiation of Byetta treatment may be the bigger impediment (1"The Pink Sheet," Feb. 2, 2009, p. 33)

You may also be interested in...

Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?

Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts